This vast reservoir of potential peptide drug candidates, combined with the rapid advancement of biotechnologies and synthesis platforms, delineates an optimistic future for VCAM-1 peptide antagonists in atherosclerosis. This evidence concerns the gene VCAM1 and atherosclerosis.